摘要

        在过去的十年里，由于下一代测序技术的进步，微生物学家已经从检测单一抗生素耐药基因（ARGs）转向检测样本中所有已知的耐药基因。这提供了大量关于细菌种群中精氨酸的变化和相对丰度的数据。然而，要将这些数据用于治疗或患者风险方面，必须在背景微生物组的背景下进行分析。利用定量PCR-ARG芯片和16srrna扩增子测序，我们试图用基因组工具鉴定健康成人粪便样本中的ARGs和细菌。在检测到的42个精氨酸中，12个符合ResCon1类精氨酸：cfxA、cphA、bacA、sul3、aadE、blaTEM、aphA1、aphA3、aph（2’）-Id、aacA/aphd、catA1和vanC。因此，我们将这12个基因描述为该人粪便微生物群的核心抗性基因，其余30个arg描述粪便微生物群中的微生物种群。优势门和属与先前在健康人粪便样本中发现的最大丰度一致。大多数检测到的ARGs与特定的细菌类群有关，这些类群通过微生物组分析得到证实。我们承认在有限样本集的情况下数据的局限性。然而，结合qPCR和微生物组分析的原理被证明有助于确定ARGs与特定分类群的关联。

        Within the past decade, microbiologists have moved from detecting single antibiotic resistance genes (ARGs) to detecting all known resistance genes within a sample due to advances in next generation sequencing. This has provided a wealth of data on the variation and relative abundances of ARGs present in a total bacterial population. However, to use these data in terms of therapy or risk to patients, they must be analyzed in the context of the background microbiome. Using a quantitative PCR ARG chip and 16S rRNA amplicon sequencing, we have sought to identify the ARGs and bacteria present in a fecal sample of a healthy adult using genomic tools. Of the 42 ARGs detected, 12 fitted into the ResCon1 category of ARGs: cfxA, cphA, bacA, sul3, aadE, bla_TEM, aphA1, aphA3, aph(2')-Id, aacA/aphd, catA1, and vanC. Therefore, we describe these 12 genes as the core resistome of this person's fecal microbiome and the remaining 30 ARGs as descriptors of the microbial population within the fecal microbiome. The dominant phyla and genera agree with those previously detected in the greatest abundances in fecal samples of healthy humans. The majority of the ARGs detected were associated with the presence of specific bacterial taxa, which were confirmed using microbiome analysis. We acknowledge the limitations of the data in the context of the limited sample set. However, the principle of combining qPCR and microbiome analysis was shown to be helpful to identify the association of the ARGs with specific taxa.

          https://www.liebertpub.com/doi/full/10.1089/mdr.2017.0199?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed&